A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience
- 1 December 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 13 (17) , 2411-2420
- https://doi.org/10.1097/00002030-199912030-00013
Abstract
SCOPUS: ar.jinfo:eu-repo/semantics/publisheKeywords
This publication has 24 references indexed in Scilit:
- The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic responseAIDS, 1999
- Metabolism of Amprenavir in Liver Microsomes: Role of CYP3A4 Inhibition for Drug InteractionsJournal of Pharmaceutical Sciences, 1998
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- HIV-Protease InhibitorsNew England Journal of Medicine, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- AmprenavirDrugs, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- In Vitro Effect of α1‐Acid Glycoprotein on the Anti‐Human Immunodeficiency Virus (HIV) Activity of the Protease Inhibitor CGP 61755: A Comparative Study with Other Relevant HIV Protease InhibitorsThe Journal of Infectious Diseases, 1997
- In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agentsAntiviral Research, 1996
- Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus TherapyThe Journal of Infectious Diseases, 1995